In recent years, there have been a number of new drugs approved for #ALS, and Muscular Dystrophy Association funding has been involved either directly or indirectly in most of those. One example is QALSODY® (tofersen), which is a drug for a genetic form of ALS, and MDA funded the first clinical trial for the predecessor to that drug. One of the key areas of #ALSresearch that we think is very important is the ability to diagnose people earlier. Most people have symptoms of ALS for a year to six months before they're actually diagnosed, so if we could back up that time and start drugs and clinical trials earlier, we feel like that would have a great impact across different types of therapies in ALS. #ALSawarenessMonth #EndALSwithMDA
We’re kicking off #ALSawarenessMonth with Ken Sutcliffe, retired Dallas Fire Fighter IAFF Local 58, and military veteran living with #ALS. Ken dedicated his career to saving lives as a U.S. Army veteran and as a fire fighter. He never thought that one day he’d be fighting for his own. Thanks to #MDA, Ken and many others like him are receiving the treatment and care that they need to live longer and love stronger. Watch as he shares his story in our newly released PSA: Answering the Call. Donations to accelerate research, advance care, and advocate for access may be made throughout the month at MDA.org/EndALS Together, we can #EndALS. Learn more: https://lnkd.in/etz5fraY #EndALSwithMDA
